Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC

Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months

Tremelimumab (75 mg) for up to 4 doses/cycles

Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)